VAY736 Emerging Drug Insight

“VAY736 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about VAY736 for Sjögren’s Syndrome in the 7MM. A detailed picture of the VAY736 for Sjögren’s Syndrome in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the VAY736 for Sjögren’s Syndrome. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VAY736 market forecast, analysis for Sjögren’s Syndrome in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Sjögren’s Syndrome.

Drug Summary

VAY736 (ianalumab) is a novel, intravenous, defucosylated, human IgG1/κ monoclonal antibody that targets the human B cell-activating factor (BAFF) of the TNF family. The BAFF receptor is predominantly expressed on B cells and is critically involved in B cell maturation, activation, and survival. VAY736 targets the BAFF receptor and competitively inhibits BAFF binding to BAFF-R, thereby blocking BAFF-R-mediated signaling in B cells. It is also engineered to effectively eliminate B cells from circulation in vivo by antibody-dependent cellular cytotoxicity (ADCC). ADCC activity of ianalumab is greatly enhanced by eliminating fucose residues from the carbohydrate moiety attached to the Fc part of the antibody.

In short, ianalumab eliminates BAFF-R + mature and immature B cells via dual mechanisms: ADCC and induction of B cell apoptosis by blocking BAFF: BAFF-R interaction and downstream survival pathway in B cells. The high baseline BAFF levels are commonly observed in B cell-driven autoimmune diseases, such as primary Sjögren’s Syndrome and others. The molecule is being developed by Novartis in partnership with MorphoSys as an antibody-based therapy.

It is currently in Phase III clinical studies for the treatment of Sjögren’s Syndrome (SS). Along with this, the molecule is also being studied for the indications, such as Pemphigus vulgaris, Rheumatoid arthritis, and others.

Scope of the Report

The report provides insights into:

•  A comprehensive product overview including the VAY736 description, mechanism of action, dosage and administration, research and development activities in Sjögren’s Syndrome.
•  Elaborated details on VAY736 regulatory milestones and other development activities have been provided in this report.
•  The report also highlights the VAY736 research and development activity in Sjögren’s Syndrome details across the United States, Europe and Japan.
•  The report also covers the patents information with expiry timeline around VAY736.
•  The report contains forecasted sales of VAY736 for Sjögren’s Syndrome till 2032.
•  Comprehensive coverage of the late-stage emerging therapies for Sjögren’s Syndrome.
•  The report also features the SWOT analysis with analyst views for VAY736 in Sjögren’s Syndrome.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VAY736 Analytical Perspective by DelveInsight

• In-depth VAY736 Market Assessment

This report provides a detailed market assessment of VAY736 in Sjögren’s Syndrome in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data of VAY736.

• VAY736 Clinical Assessment

The report provides the clinical trials information of VAY736 for Sjögren’s Syndrome covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

•  In the coming years, the market scenario for Sjögren’s Syndrome is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
•  The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VAY736 dominance.
•  Other emerging products for Sjögren’s Syndrome are expected to give tough market competition to VAY736 and launch of late-stage emerging therapies in the near future will significantly impact the market.
•  A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VAY736 in Sjögren’s Syndrome.
•  Our in-depth analysis of the forecasted sales data of VAY736 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VAY736 in Sjögren’s Syndrome.

Key Questions

•  What is the product type, route of administration and mechanism of action of VAY736?
•  What is the clinical trial status of the study related to VAY736 in Sjögren’s Syndrome and study completion date?
•  What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VAY736 development?
•  What are the key designations that have been granted to VAY736 for Sjögren’s Syndrome?
•  What is the forecasted market scenario of VAY736 for Sjögren’s Syndrome?
•  What are the forecasted sales of VAY736 in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
•  What are the other emerging products available in Sjögren’s Syndrome and how are they giving competition to VAY736 for Sjögren’s Syndrome?
•  Which are the late-stage emerging therapies under development for the treatment of Sjögren’s Syndrome?